5 Stocks Advancing The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 119 points (0.7%) at 16,493 as of Wednesday, Jan. 15, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,941 issues advancing vs. 990 declining with 158 unchanged.

The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Globus Medical ( GMED), up 4.6%, Edwards Life ( EW), up 3.4% and Express Scripts ( ESRX), up 0.8%. On the negative front, top decliners within the industry include HCA Holdings ( HCA), down 1.0%, Grifols ( GRFS), down 1.0% and Smith & Nephew ( SNN), down 0.7%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. NuVasive ( NUVA) is one of the companies pushing the Health Services industry higher today. As of noon trading, NuVasive is up $2.62 (7.8%) to $36.40 on heavy volume. Thus far, 1.1 million shares of NuVasive exchanged hands as compared to its average daily volume of 460,500 shares. The stock has ranged in price between $36.35-$37.25 after having opened the day at $36.62 as compared to the previous trading day's close of $33.78.

NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedurally integrated solutions for the spine. The company's products focus on applications for spine fusion surgery. NuVasive has a market cap of $1.5 billion and is part of the health care sector. Shares are up 4.5% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts who rate NuVasive a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates NuVasive as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full NuVasive Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

Masimo's Stock Is a Great Buy Right Now

NXPI, AAPL, C: Jim Cramer's Views

Cramer: Demand Lifts Defense, Aerospace, Cyber-Security, Regional Bank Stocks

NuVasive (NUVA) Stock Tumbles on Q3 Revenue Miss, Outlook